The Efficacy of Ergogenic Agents in Athletic Competition: Part II: Other Performance-Enhancing Agents

Abstract

Spanish

OBJECTIVE:

To summarize the literature describing the epidemiology, pharmacology, efficacy, and adverse effects associated with growth hormone (GH), caffeine, aerobic metabolism facilitator (AMF), and sympathomimetic use among athletes.

DATA SOURCES:

Relevant articles were identified from a MEDLINE search using the search terms “Doping in Sports”, “Blood”, “Caffeine”, “Cocaine”, “Erythropoeitin”, “Somatotropin”, and “Sympathomimetics (exploded).” Additional references were found in bibliographies of these articles.

STUDY SELECTION/DATA EXTRACTION:

We reviewed studies of ergogenic drug (ED) use among athletes. Interpretation of these studies is difficult because of poor research design and the paucity of information available. This necessitated the inclusion of many anecdotal or conjectural reports in our review.

DATA SYNTHESIS:

There are no studies documenting an ergogenic effect associated with GH use in humans or animals. It is still unknown whether GH abuse causes adverse effects in healthy adults, although GH-induced acromegaly has been suspected. Amphetamines, cocaine, and caffeine are thought to improve performance via enhanced concentration among athletes. Amphetamines and cocaine may increase aggressiveness. The ergogenic effects of other sympathomimetics including ephedrine and phenylpropanolamine are unclear. AMFs (e.g., blood doping, epoetin) enhance aerobic metabolism and endurance by increasing the oxygen-carrying capacity of the blood. Risks associated with excessive AMF use include increased blood viscosity and clotting.

CONCLUSIONS:

Athletes view EDs as an essential component for success. Without adequate intervention measures, ED abuse is likely to continue unchecked.

Get full access to this article

View all access options for this article.

References

Package insert. Protropin (somatrem). South San Francisco, CA: Genentech, March 1991.

Duchaine

. Underground steroid handbook II. Venice, CA: HLR Technical Books, 1989.

Macintyre

. Growth hormone and athletes. Sports Med 1987; 4: 129–42.

Cowart

. Human growth hormone: The latest ergogenic aid?. Physician Sportsmed 1988; 16: 175–85.

Wadler

Hainline

. Human growth hormone. In: Drugs and the athlete. Philadelphia: FA Davis, 1989: 70–4.

Taylor

. Synthetic human growth hormone: A call for federal control. Physician Sportsmed 1988; 16: 189–92.

Council on Scientific Affairs . Drug abuse in athletes: Anabolic steroids and human growth hormone. JAMA 1988; 259: 1703–5.

Kuret

Murad

. Adenohypophyseal hormones and related substances. In: Gilman

Rall

Nies

Taylor

, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Elmsford, NY: Pergamon Press, 1990: 1334–60.

Van Vliet

Styne

Kaplan

Grumbach

. Growth hormone treatment for short stature. N Engl J Med 1983; 309: 1016–22.

10.

Spiliotis

August

Hung

Sonis

Mendelson

Bkercu

. Growth hormone neurosecretory dysfunction. A treatable cause of short stature. JAMA 1984; 251: 2223–30.

11.

Rosenfeld

Hintz

Johanson

Brasel

Burstein

Chernausek

. Methionyl human growth hormone and oxandrolone in Turner syndrome: Preliminary results of a prospective randomized trial. J Pediatr 1986; 109: 936–43.

12.

Duchaine

. Underground steroid handbook. Marina Del Rey, CA, 1982.

13.

Apostolakis

Deligiannis

Madena-Pyrgaki

. The effects of human growth hormone administration on the functional status of rat atrophied muscle following immobilization. Physiologist 1980; 23 (suppl): S111–2.

14.

Bigland

Jehring

. Muscle performance in rats, normal and treated with growth hormone. J Physiol (Lond) 1952; 116: 129–36.

15.

Taylor

. Anabolic steroids and the athlete. Jefferson, NC: McFarland & Co., 1982.

16.

Laties

Weiss

. The amphetamine margin in sports. Fed Proc 1981; 40: 2689–92.

17.

Heyrodt

Weissenstein

. Uber steigerung korperlicher leistungfahigkeit keit durch pervitin. Arch Exp Pathol Pharmacol 1940; 195: 273–5.

18.

Wadler

Hainline

. Amphetamine. In: Drugs and the athlete. Philadelphia: FA Davis, 1989: 75–86.

19.

Hoffman

Lefkowitz

. Catecholamines and sympathomimetic drugs. In: Gilman

Rail

Nies

Taylor

, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Elmsford, NY: Pergamon Press, 1990: 187–220.

20.

Smith

Beecher

. Amphetamine sulfate and athletic performance: 1. Objective effects. JAMA 1959; 170: 542–57.

21.

Karpovich

. Effect of amphetamine sulfate on athletic performance. JAMA 1959; 170: 558–61.

22.

Chandler

Blair

. The effect of amphetamines on selected physiological components related to athletic success. Med Sci Sports Exerc 1980; 12: 65–9.

23.

Blum

Stern

Melville

. A comparative evaluation of the action of depressant and stimulant drugs on human performance. Psychopharmacologia 1964; 6: 173–7.

24.

Domino

Albers

Potvin

Repa

Tourtellotte

. Effects of d-amphetamine on quantitative measures of motor performance. Clin Pharmacol Ther 1972; 13: 251–7.

25.

Belleville

Dorey

Belleville

. Effects of nefopam on visual tracking. Clin Pharmacol Ther 1979; 26: 457–63.

26.

Evans

Martz

Lemberger

Rodda

Forney

. Effects of dextroamphetamine on psychomotor skills. Clin Pharmacol Ther 1976; 19: 777–81.

27.

Mandell

Stewart

Russo

. The Sunday syndrome: From kinetics to altered consciousness. Fed Proc 1981; 40: 2693–8.

28.

Wadler

Hainline

. Cocaine. In: Drugs and the athlete. Philadelphia: FA Davis, 1989: 87–100.

29.

Fischman

Schuster

Resnekov

Shick

JFE

Krasnegor

Fennell

. Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch Gen Psychiatry 1976; 33: 983–9.

30.

Farrar

Kearns

. Cocaine: Clinical pharmacology and toxicology. J Pediatr 1989; 115: 665–75.

31.

Pomerantz

. The mugging in Chicago: Sympathy, respect in short supply. The Washington Post 1986 Nov 26; Sect. E: 4 (col. 1).

32.

Cook

Jeffcoat

Perez-Reyes

. Pharmacokinetic studies of cocaine and phencyclidine in man. In: Barnett

Chiang

, eds. Pharmacokinetics and pharmacodynamics of psychoactive drugs: A research monograph. Foster City, CA: Biomedical Publications, 1985: 48–74.

33.

Anggard

Jonsson

Hogmark

Gunne

. Amphetamine metabolism in amphetamine psychosis. Clin Pharmacol Ther 1973; 14: 870–80.

34.

Cregler

. Adverse health consequences of cocaine abuse. J Natl Med Assoc 1989; 81: 27–38.

35.

Post

Kopanda

Black

. Progressive effects of cocaine on behavior and central amine metabolism in rhesus monkeys: Relationship to kindling and psychosis. Biol Psychiatry 1976; 11: 403–19.

36.

Sidney

Lefcoe

. The effects of ephedrine on the physiological and psychological responses to submaximal and maximal exercises in man. Med Sci Sports 1977; 9: 95–9.

37.

Martin

Sloan

Sapira

Jasinski

. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971; 12: 245–58.

38.

Woolverton

Johanson

De la Garza

Ellis

Seiden

Schuster

. Behavioral and neurochemical evaluation of phenylpropanolamine. J Pharmacol Exp Ther 1986; 237: 926–30.

39.

Wadler

Hainline

. Phenylpropanolamine, ephedrine, and the “look-alikes.” In: Drugs and the athlete. Philadelphia: FA Davis, 1989: 101–6.

40.

Lake

Masson

Quirk

. Psychiatric side effects attributed to phenylpropanolamine. Pharmacopsychiatry 1988; 21: 171–81.

41.

Wadler

Hainline

. Caffeine. In: Drugs and the athlete. Philadelphia: FA Davis, 1989: 107–13.

42.

Costill

Dalsky

Fink

. Effects of caffeine ingestion on metabolism and exercise performance. Med Sci Sports 1978; 10: 155–8.

43.

Ivy

Costill

Fink

Lower

. Influence of caffeine and carbohydrate feeding on endurance performance. Med Sci Sports 1979; 11: 6–11.

44.

Essig

Costill

Van Handel

. Effects of caffeine ingestion on utilization of muscle glycogen and lipid during leg ergometer cycling. Int J Sports Med 1980; 1: 86–90.

45.

Perkins

Williams

. Effects of caffeine upon maximal muscular endurance of females. Med Sci Sports 1975; 7: 221–4.

46.

Powers

Byrd

Tulley

Callender

. Effects of caffeine ingestion on metabolism and performance during graded exercise. Eur J Appl Physiol 1983; 50: 301–7.

47.

Lecos

. The latest caffeine scorecard. FDA Consumer 1984; 18 (2): 14–6.

48.

Diagnostic and statistical manual of mental disorders. 3rd ed., revised. Washington, DC: American Psychiatric Association, 1987: 138.

49.

Jones

Pedoe

DST

. Blood doping: A literature review. Br J Sports Med 1989; 23: 84–8.

50.

Eichner

. Blood doping: Results and consequences from the laboratory and the field. Physician Sportsmed 1987; 15: 120–9.

51.

Gledhill

. Blood doping and related issues: A brief review. Med Sci Sports Exerc 1982; 14: 183–9.

52.

Sawka

Young

Muza

Gonzalez

Pandolf

. Erythrocyte reinfusion and maximal aerobic power: An examination of modifying factors. JAMA 1987; 257: 1496–9.

53.

Flaharty

Grimm

Vlasses

. Epoetin: Human recombinant erythropoietin. Clin Pharm 1989; 8: 769–82.

54.

Adamson

Vapnek

. Recombinant erythropoietin to improve athletic performance (letter). N Engl J Med 1991; 324: 698–9.

55.

Eschbach

Egrie

Downing

Browne

Adamson

. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73–8.

56.

Kim

. A bad boost. Sports Illus 1990 Nov 26: 29.

57.

Chen

. Undetectable dialysis drug is tied to athletes' deaths. The Los Angeles Times 1990 May 22; Sect. A:1 (col. 5), A: 15 (col. 1).